BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 31154289)

  • 1. Efficacy and safety of etanercept combined plus methotrexate and comparison of expression of pro-inflammatory factors expression for the treatment of moderate-to-severe plaque psoriasis.
    Yu Q; Tong Y; Cui L; Zhang L; Gong Y; Diao H; Gao F; Shi Y
    Int Immunopharmacol; 2019 Aug; 73():442-450. PubMed ID: 31154289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Etanercept biosimilar (recombinant human tumor necrosis factor-α receptor II: IgG Fc fusion protein) and methotrexate combination therapy in Chinese patients with moderate-to-severe plaque psoriasis: a multicentre, randomized, double-blind, placebo-controlled trial.
    Liu LF; Chen JS; Gu J; Xu JH; Jin HZ; Pang XW; Wang G; Yu C; Song ZQ; Guo ZP; Li W; Lai W; Cui PG; Chen M; Fang H; Lyu CZ; Li YZ; Sun Q; Xie HF; Liu XM; Gao XH; Shi YL; Zhao NQ; Zhang W; Zheng M
    Arch Dermatol Res; 2020 Aug; 312(6):437-445. PubMed ID: 31873772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
    Gottlieb AB; Langley RG; Strober BE; Papp KA; Klekotka P; Creamer K; Thompson EH; Hooper M; Kricorian G
    Br J Dermatol; 2012 Sep; 167(3):649-57. PubMed ID: 22533447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.
    Liu Y; Qin G; Meng Z; Du T; Wang X; Tang Y; Cao J
    Inflammopharmacology; 2019 Feb; 27(1):57-66. PubMed ID: 30242748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.
    Xie F; Wang R; Zhao ZG; Meng XF; Lin BW; Yang J; Wang WJ; Ding XY; Yang Y; Zhao H; Li CX; Li HJ; Zhou Y
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):943-947. PubMed ID: 29270758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between serum interleukin-17A and clinical response to tofacitinib and etanercept in moderate to severe psoriasis.
    Fitz L; Zhang W; Soderstrom C; Fraser S; Lee J; Quazi A; Wolk R; Mebus CA; Valdez H; Berstein G
    Clin Exp Dermatol; 2018 Oct; 43(7):790-797. PubMed ID: 29748971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy.
    Zachariae C; Mørk NJ; Reunala T; Lorentzen H; Falk E; Karvonen SL; Johannesson A; Claréus B; Skov L; Mørk G; Walker S; Qvitzau S
    Acta Derm Venereol; 2008; 88(5):495-501. PubMed ID: 18779890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can etanercept treatment failure in moderate-to-severe psoriasis be overcome by addition of low-dose methotrexate? A single-center experience.
    Sherman S; Hodak E; Pavlovsky L
    J Dermatolog Treat; 2018 Nov; 29(7):666-670. PubMed ID: 29466892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etanercept combined with methotrexate for high-need psoriasis.
    Driessen RJ; van de Kerkhof PC; de Jong EM
    Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
    Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
    J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial.
    Papp K; Thaçi D; Marcoux D; Weibel L; Philipp S; Ghislain PD; Landells I; Hoeger P; Kotkin C; Unnebrink K; Seyger M; Williams D
    Lancet; 2017 Jul; 390(10089):40-49. PubMed ID: 28478975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
    Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
    BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of psoriasis severity and inflammatory responses under concomitant treatment with methotrexate plus micronutrients for psoriasis vulgaris: a randomized double blind trial.
    Yousefzadeh H; Jabbari Azad F; Banihashemi M; Rastin M; Mahmoudi M
    Acta Dermatovenerol Alp Pannonica Adriat; 2017 Mar; 26(1):3-9. PubMed ID: 28352928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trial.
    Kemeny L; Amaya M; Cetkovska P; Rajatanavin N; Lee WR; Szumski A; Marshall L; Mahgoub EY; Aldinç E
    BMC Dermatol; 2015 May; 15():9. PubMed ID: 25994179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
    Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
    Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
    Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
    Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
    Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
    Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Refractory erythrodermic psoriasis in a child with an excellent outcome by using etanercept.
    Fraga NA; Paim Mde F; Follador I; Ramos AN; Rêgo VR
    An Bras Dermatol; 2011; 86(4 Suppl 1):S144-7. PubMed ID: 22068796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
    Gisondi P; Del Giglio M; Cotena C; Girolomoni G
    Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.